AR and posterior cortical atrophy: Recent work from the Tang lab [127] in human CRPC specimens and using both genetically engineered AR-null PCa cells and paired androgen-dependent (AD) and androgen-independent (AI) PCa xenograft models, demonstrates that while AR+ PCa cells, as expected, show exquisite sensitivity to enzalutamide, the AR−/lo PCa cells are enzalutamide-resistant de novo.